Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at Morgan Stanley from $49.00 to $45.00. They now have an "overweight" rating on the stock.
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at BMO Capital Markets from $67.00 to $25.00. They now have an "outperform" rating on the stock.
Silence Therapeutics plc (NASDAQ: SLN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $6.00 to $4.00. They now have a "sell" rating on the stock.